SISAQOLSISAQOL

PRESS RELEASE: Generating recommendations for the design, analysis and interpretation of patient- reported outcome (PRO) data for cancer clinical trials: the launch of SISAQOL-IMI

An international multidisciplinary consortium, co-led by the European Organization for Research and Treatment of Cancer (EORTC) and Boehringer Ingelheim (BI), has been convened to generate recommendations to standardize the use, analysis, and interpretation of patient reported outcome (PRO) data in cancer clinical trials

PRESS RELEASE: Generating recommendations for the design, analysis and interpretation of patient- reported outcome (PRO) data for cancer clinical trials: the launch of SISAQOL-IMI2022-10-27T07:41:54+01:00

Read our systematic review on patient-reported outcomes in metastatic breast cancer

There is little consensus on how PRO and HRQoL data should be analyzed in randomized clinical trials. This systematic review evaluates the current situation in the field of metastatic breast cancer, revealing the many statistical issues that need to be addressed to improve the analysis and interpretation of PRO data.

Read our systematic review on patient-reported outcomes in metastatic breast cancer2022-10-27T07:46:56+01:00

The SISAQOL initiative during the 5th EORTC Quality of Life Conference in Brussels

Several SISAQOL Consortium members presented during the 5 EORTC Quality of Life Conference in Brussels. Recordings from the conference presentations, including the presentation on the SISAQOL work, are available on the conference website.

The SISAQOL initiative during the 5th EORTC Quality of Life Conference in Brussels2022-10-27T07:48:40+01:00
Go to Top